Leerink Partners' Ominous Sign on MannKind (MNKD)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Leerink Partners' Ominous Sign on MannKind (MNKD)

Piper Jaffray Maintains Underweight on MannKind (MNKD) Following Results and Grim Outlook

November 10, 2015 7:01 AM EST

Piper Jaffray analyst Joshua Schimmer reiterated an Underweight rating and $1.50 price target on MannKind (NASDAQ: MNKD) following results.

Schimmer commented, "While cost-cutting measures will help curtail the cash burn, the disappointing launch of Afrezza and increasing net-debt position seem to be making the... More

MannKind (MNKD) Misses Q3 EPS by 1c

November 9, 2015 10:18 AM EST

MannKind (NASDAQ: MNKD) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).

For the three and nine months ended September 30, 2015, product shipments of Afrezza, our novel rapid-acting inhaled insulin therapy, were $4.1 million and $17.1 million, respectively, which we recorded as deferred product... More